Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M81,069Revenue $M16,385Net Margin (%)15.6Z-Score5.1
Enterprise Value $M81,716EPS $1.5Operating Margin %18.9F-Score5
P/E(ttm))28.2Cash Flow Per Share $2.8Pre-tax Margin (%)17.6Higher ROA y-yY
Price/Book5.210-y EBITDA Growth Rate %0.7Quick Ratio1.6Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %-13.3Current Ratio1.9Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %114ROA % (ttm)6.6Higher Current Ratio y-yY
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)16.9Less Shares Outstanding y-yN
Payout Ratio %82.0Shares Outstanding M1,657ROI % (ttm)5.7Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 48.92-8%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 48.92-8%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 48.92-8%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 48.92-8%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 48.92-8%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 48.92-4%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 48.9212%Add 20.26%24,459,861
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 48.9212%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 48.9213%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 48.9213%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 48.9213%Add 302.66%66,520
BMYRay Dalio 2013-06-30 Sold Out -0.07%$39.68 - $47.68
($43.41)
$ 48.9213%Sold Out0
BMYPrem Watsa 2013-06-30 Sold Out -0.01%$39.68 - $47.68
($43.41)
$ 48.9213%Sold Out0
BMYVanguard Health Care Fund 2013-03-31 Add0.96%$32.59 - $41.19
($36.62)
$ 48.9234%Add 49.53%17,948,561
BMYRay Dalio 2013-03-31 Add0.05%$32.59 - $41.19
($36.62)
$ 48.9234%Add 267.87%181,140
BMYJohn Hussman 2013-03-31 Sold Out -0.64%$32.59 - $41.19
($36.62)
$ 48.9234%Sold Out0
BMYJames Barrow 2013-03-31 Sold Out -0.05%$32.59 - $41.19
($36.62)
$ 48.9234%Sold Out0
BMYJohn Hussman 2012-12-31 Reduce-0.2%$30.81 - $34.38
($32.89)
$ 48.9249%Reduce -25%750,000
BMYJames Barrow 2012-12-31 Reduce-0.02%$30.81 - $34.38
($32.89)
$ 48.9249%Reduce -22.36%795,409
BMYRay Dalio 2012-12-31 Reduce-0.01%$30.81 - $34.38
($32.89)
$ 48.9249%Reduce -21.64%49,240
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Ronald Muhlenkamp 2014-03-31212,0150.011.9New Buy
BMY Ray Dalio 2014-03-314,42800New Buy
BMY Vanguard Health Care Fund 2014-03-3129,437,7611.784.3+20.35%
BMY Jean-Marie Eveillard 2014-03-3116,52000
BMY Dodge & Cox 2014-03-3179,12100-1%
BMY Mario Gabelli 2014-03-31686,7850.040.19-6.02%
BMY Joel Greenblatt 2014-03-31000Sold Out
BMY George Soros 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Caldarella Joseph CSVP & Controller 2014-03-13Sell9,137$55.2-11.01view
ANDREOTTI LAMBERTOCEO 2014-03-10Sell100,000$55.52-11.53view
Schmukler Louis SPres., Global Mfg. & Supply 2014-03-10Sell8,799$55.81-11.99view
CORNELIUS JAMES MDirector 2014-03-05Sell100,000$55.82-12view
Schmukler Louis SPres., Global Mfg. & Supply 2014-02-28Sell6,088$54.49-9.86view
Caforio GiovanniEVP & Chief Commercial Officer 2014-02-24Sell41,563$54.44-9.77view
Elicker John ESVP Pub Affairs & Inv Relation 2014-02-19Sell9,534$54.22-9.41view
Cuss Francis MEVP & CSO 2014-02-18Sell29,800$54.61-10.05view
LEUNG SANDRAGeneral Counsel & Secretary 2014-02-14Sell10,490$54.28-9.51view
Bancroft Charles AEVP & CFO 2014-02-14Sell52,963$54.35-9.62view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Vanguard Health Care Fund’s Top Five Feb 10 2014 
Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


More From Other Websites
Perrigo, Actelion Tax Targets Abroad for U.S. Drugmakers Jul 20 2014
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis Jul 18 2014
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to... Jul 17 2014
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to... Jul 17 2014
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to... Jul 17 2014
Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14) Jul 16 2014
Perrigo retreats after analyst sees limited potential buyers Jul 15 2014
Is Bristol-Myers Squibb Overvalued? Jul 14 2014
Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug Jul 11 2014
Senators Ask Gilead To Explain Sovaldi Pricing Jul 11 2014
Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Bristol-Myers Squibb plans for Third Quarter... Jul 10 2014
Bristol seeks cancer drug nod Jul 10 2014
Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement... Jul 10 2014
Bristol-Myers announces plans for Q3 submission of Opdivo BLA Jul 10 2014
Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application... Jul 10 2014
Bristol-Myers Seeking Nivolumab Approval In Melanoma Jul 10 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide